(Doriden), methyprylone (Noludar), ethchlorvynol (Arvynol) , and meprobamate (Miltown, Equanil) (Brit. med. 7., 1964; Wood and Flippin, 1965) . The clinical features described in these studies correspond very closely with those found in our patient.
Methaqualone has been shown to be a potent hypnotic (Parsons and Thomson, 1961 ; Duchastel, 1962) . It is marketed in the United Kingdom as Melsedin, and in combination with diphenhydramine as Mandrax. It is sold in the U.S.A. as Quaalude. Melsedin was described as a non-barbiturate hypnotic that "produces natural sleep" and to which neither tolerance nor addiction had been attributed. The makers have told us that they now know of four cases of addiction, in addition to the one reported here, three of the patients concerned having a history of addiction also to barbiturates or alcohol (J. W. Buckler, personal communication, 1966) .
Mandrax is claimed to have an action that is " quite different from that of the barbiturates and almost all other hypnotics." No addiction had been reported to the makers, who pointed out (February 1966) J3., 1967, 3, 93-94 Before the introduction of corticosteroids in 1949 splenectomy and blood transfusions were the only well-established treatments for autoimmune haemolytic anaemia (Dacie, 1954 ; Schwartz and Dameshek, 1962) . Corticosteroids rapidly became the treatment of choice, splenectomy being reserved for refractory cases. Dameshek and Schwartz (1960) reported the use of purine antagonists in the management of autoimmune haemolytic anaemia, and this has now been accepted as an additional treatment. It has been suggested that primary thrombocytopenic purpura and acquired haemolytic anaemia might have a common aetiology (Evans et al., 1951) (6.4 kg.) in weight. During a 23-days course of treatment wkh mercaptopurine the platelet count ranged between 40,000 and 180,000/cu. mm., and the white cell count fell steadily from 21,000 soon after admission to 3,200 (see Chart). The patient was discharged without purpura on 8 November, with a platelet count of 270,000/cu. mm. He was not receiving treatment. Five days later, having developed diffuse purpura, he was readmitted to hospital with a platelet count of 33,000/cu. mm. Prednisone 20 mg./day was started immediately, but when, on 19
November, a platelet count was only 62,000/cu. umm. mercaptopurine was reintroduced at a dosage of 50 mg./day and the prednisone cut to S mg./day. Three days later a platelet count was 204,000/cu. mm., and during the next two and a half months on this drug regimen it remained between 100,000 and 200,000/cu. mm.
On 1 February 1966 the dosage of mercaptopurine was halved to 25 mg./day, and this was followed on 1 March by a recurrence of purpura (platelets 58,000/cu. mm.). Mercaptopurine was increased to 50 mg./day, and a week later there was no new purpura and the platelets were 360,000/cu. mm. On this regimen of treatment the patient remained well until 3 July, when he developed purpura.
When seen at the hospital two days later a platelet count was 18,000/ cu. mm., W.B.C. 5,600/cu. mm., and Hb 16 g./100 ml. No cause for the relapse of purpura was established, and the dosage of prednisone was increased to 20 mg./day. Eight days later there was no sign of purpura, a platelet count was 186,000/cu. mm. and W.B.C. 10,800/cu. mm. Since then the dosage of prednisone has been gradually reduced, and at the time of writing the patient was very well, had no leucopenia, and was able to work as a clerk. On several occasions during the last few months when the prednisone was omitted for a few days he has complained of feeling unwell, but this always cleared as soon as the prednisone was restarted.
DIscusSION
The occurrence of autoimmune haemolytic anaemia and thrombocytopenia has been recognized for many years (Evans and Duane, 1949) . The frequency of their association is not known, but in a series of 83 cases of autoimmune haemolytic anaemia (warm antibody) reported by Dausset and Colombani (1959) 13.2% had a concurrent thrombocytopenia.
In addition to corticosteroids antimetabolite drugs have recently been reputed to be beneficial in the treatment of haemolytic anaemia and thrombocytopenia. Richmond et al. (1963) reported a case in which a fulminating haemolytic anaemia and thrombocytopenia developed some time after splenectomy for idiopathic thrombocytopenia. Large doses of corticosteroids were ineffective and thymic irradiation produced only transitory improvement. The thrombocytopenia and anaemia were finally controlled by Imuran (azathioprine) and actinomycin C. Matthews (1965) reported the successful use of Imuran in the treatment of a patient with idiopathic autoimmune haemolytic anaemia and idiopathic thrombocytopenia associated with diffuse hypergammaglobulinaemia, amyloidosis, hypoalbuminaemia, and plasmacytosis. Bouroncle and Doan (1966) reported seven cases of refractory idiopathic thrombocytopenic purpura treated with Imuran. In four of their cases several months' treatment with prednisone and Imuran led to a remission of thrombocytopenia, which was sustained when the drugs were stopped. In two of their cases a definite improvement in platelet count accompanied continuous treatment with the same drugs.
In this case thrombocytopenia developed two years after the appearance of an autoimmune haemolytic anaemia, which was then in remission. Prednisone successfully controlled the thrombocytopenia after splenectomy had failed. A further two years later thrombocytopenia relapsed. Large doses of corticotrophin produced a temporary remission, but in view of the rapid development of signs of corticosteroid overdosage alternative treatment was essential. A trial of mercaptopurine proved successful, and the patient remained well on a maintenance dosage of mercaptopurine and prednisone. This case supports the finding of Bouroncle and Doan (1966) that corticosteroids seem to have an additive effect with antimetabolites in obtaining remission of thrombocytopenia.
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